Non-Small Cell Lung Cancer

Treatment Disparities in Elderly Patients With Non-Small Cell Lung Cancer

Treatment Disparities in Elderly Patients With Non-Small Cell Lung Cancer

Many octogenarians and nonagenarians with non-small cell lung cancer do not receive cancer-directed care.

Chemotherapy Followed by Radiotherapy Improves Survival in NSCLC

Chemotherapy Followed by Radiotherapy Improves Survival in NSCLC

By

Adjuvant chemotherapy administered prior to, rather than concurrently with, radiotherapy improves survival outcomes among patients with NSCLC.

Lobectomy vs Stereotactic Body Radiation Therapy in Non-Small Cell Lung Cancer

Lobectomy vs Stereotactic Body Radiation Therapy in Non-Small Cell Lung Cancer

Survival is better with lobectomy than SBRT in patients with NSCLC.

Osimertinib May Improve Outcomes in <i>EGFR</i> Mutation-Postive NSCLC

Osimertinib May Improve Outcomes in EGFR Mutation-Postive NSCLC

Treatment with osimertinib is associated with longer progression-free survival in patients with previously untreated EGFR mutation-positive advanced non-small-cell lung cancer.

Non-Small Cell Lung Cancer: Trends in Stage I Treatment

Non-Small Cell Lung Cancer: Trends in Stage I Treatment

Between 2000 and 2010, researchers identified a decline in the number of patients with stage I NSCLC who remained untreated.

Non-Small Cell Lung Cancer: Nivolumab vs Docetaxel for Long-Term Efficacy

Non-Small Cell Lung Cancer: Nivolumab vs Docetaxel for Long-Term Efficacy

By

Results of two phase 3 studies found that nivolumab provided superior overall survival vs docetaxel in people with non-small cell lung cancer.

Quality of Life Benefits of Yoga in Non-Small Cell Lung Cancer

Quality of Life Benefits of Yoga in Non-Small Cell Lung Cancer

By

Patients with NSCLC experienced improvements in both function and quality of life with yoga therapy.

Potential Delays in Non-Small Cell Lung Cancer Therapy

Potential Delays in Non-Small Cell Lung Cancer Therapy

By

Study results stress the importance of a multiethnic support system for patients needing to overcome communication barriers.

Gefitinib Treatment Should Be Avoided Prior to Chemotherapy in Non-small Cell Lung Cancer

Gefitinib Treatment Should Be Avoided Prior to Chemotherapy in Non-small Cell Lung Cancer

By

First generation EGFR tyrosine kinase inhibitors should be used in combination with chemotherapy if a patient has progressive EGFR mutation-positive non-small cell lung cancer.

Dacomitinib vs Gefitinib for Progression-Free Survival in Non-small Cell Lung Cancer

Dacomitinib vs Gefitinib for Progression-Free Survival in Non-small Cell Lung Cancer

By

Dacomitinib improved progression-free survival in patients with non-small cell lung cancer.

Durvalumab Linked to Longer Progression-Free Survival in NSCLC

Durvalumab Linked to Longer Progression-Free Survival in NSCLC

Fewer than 30% of patients undergoing durvalumab therapy experienced either grade 3 or 4 adverse events.

Does CT Scan at Follow-up Improve Resected NSCLC Survival?

Does CT Scan at Follow-up Improve Resected NSCLC Survival?

By

Recommendations to include CT scans as standard follow-up procedure is based on poor evidence.

Improving Anorexia-Cachexia in Non-small Cell Lung Cancer

Improving Anorexia-Cachexia in Non-small Cell Lung Cancer

By

Data from 5 phase 2/3 studies demonstrate improved weight and body mass in patients with NSCLC receiving anamorelin.

Improving Survival in Resected NSCLC With Adoptive Cellular Immunotherapy

Improving Survival in Resected NSCLC With Adoptive Cellular Immunotherapy

By

A phase 3 trial examined the efficacy of chemoimunnotherapy vs chemotherapy alone in postsurgical patients with non-small cell lung cancer.

FDA: Priority Review for Alectinib for ALK-positive NSCLC

FDA: Priority Review for Alectinib for ALK-positive NSCLC

By

Priority review for alectinib was granted based on evidence from the phase 3 ALEX and J-ALEX clinical trials.

FDA: Durvalumab Granted Breakthrough Therapy Designation for NSCLC

FDA: Durvalumab Granted Breakthrough Therapy Designation for NSCLC

By

Durvalumab can be used to treat patients with locally advanced, unrescetable NSCLC, who do not relapse after platinum-based chemoradiation.

Predicting Overall Survival With Neutrophil-Lymphocyte Ratio in NSCLC

Predicting Overall Survival With Neutrophil-Lymphocyte Ratio in NSCLC

By

Valuable information regarding patients' life expectancy can be collected through neutrophil-lymphocyte ratio biomarkers.

Efficacy of Neoadjuvant Nivolumab in NSCLC

Efficacy of Neoadjuvant Nivolumab in NSCLC

By

Researchers considered the response rate "encouraging" and comparable to cisplatin-based neoadjuvant therapy outcomes.

Survival Outcomes With Nivolumab vs Chemotherapy for Stage IV, Recurrent NSCLC

Survival Outcomes With Nivolumab vs Chemotherapy for Stage IV, Recurrent NSCLC

Findings in patients with previously untreated disease with PD-L1 expression level of 5%.

Improving NSCLC Outcomes With Midtreatment FDG-PET-Driven Radiation Tx

Improving NSCLC Outcomes With Midtreatment FDG-PET-Driven Radiation Tx

By

Increased radiation therapy based on midtreatment residual tumor FDG-PET may improve local control among patients with advanced NSCLC.

Survival Rate Increases With Adjuvant Gefitinib in NSCLC

Survival Rate Increases With Adjuvant Gefitinib in NSCLC

By

Adjuvant gefitnib increases disease-free survival for patients with stage II to III non-small lung cancer.

Glucose Dependency in Squamous Cell vs Adenocarcinoma NSCLC Tumors

Glucose Dependency in Squamous Cell vs Adenocarcinoma NSCLC Tumors

By

Data can be used to target the development of new drugs for treating squamous cell carcinomas.

Does Docetaxel Plus Selumetinib in NSCLC Increase Progression-Free Survival?

Does Docetaxel Plus Selumetinib in NSCLC Increase Progression-Free Survival?

The added combination of selumetinib with docetaxel did not improve progression-free survival among patients previously treated for advanced NSCLC.

Vaccine Therapies Show Promise As Lung Cancer Tx

Vaccine Therapies Show Promise As Lung Cancer Tx

By

Developed in Cuba, the TG4010 and CIMAvax-EGF vaccines are undergoing clinical study in the US.

Alectinib Safe and Effective for Non-Small Cell Lung Cancer

Alectinib Safe and Effective for Non-Small Cell Lung Cancer

Two new medications may improve survival for patients with specific types of advanced non-small-cell lung cancer.

Sequental Durvalumab Ups Progression-Free Survival in NSCLC

Sequental Durvalumab Ups Progression-Free Survival in NSCLC

By

Participants in the phase 3 PACIFIC trial randomly received sequential treatment with either durvalumab or placebo.

Alectinib Therapy Linked To Progression-Free Survival In ALK-Positive NSCLC

Alectinib Therapy Linked To Progression-Free Survival In ALK-Positive NSCLC

By

Alectinib, a selective ALK inhibitor, was found to have an objective response rate of 92% among patients with ALK-positive NSCLC.

FDA Approves For Combination Pembrolizumab Plus Pemetrexed/Carboplatin Therapy For NSCLC

FDA Approves For Combination Pembrolizumab Plus Pemetrexed/Carboplatin Therapy For NSCLC

By

Approval was based on tumor response rate and progression-free survival data, gathered from the KEYNOTE-021 study.

FDA Grants Accelerated Approval to Brigatinib for Metastatic NSCLC

FDA Grants Accelerated Approval to Brigatinib for Metastatic NSCLC

The Food and Drug Administration (FDA) has granted accelerated approval to Alunbrig (brigatinib; ARIAD) tablets.

Investigational Drug for NSCLC Granted Breakthrough Therapy Designation

Investigational Drug for NSCLC Granted Breakthrough Therapy Designation

By

FDA grants Pfizer's lorlatinib the Breakthrough Therapy designation for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.

Sign Up for Free e-newsletters